Silvercrest Asset Management’s GSK GSK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$17.3M Sell
313,984
-14,780
-4% -$801K 0.13% 215
2025
Q4
$16.1M Hold
328,764
0.11% 241
2025
Q3
$14.2M Sell
328,764
-600
-0.2% -$23.4K 0.09% 261
2025
Q2
$12.6M Sell
329,364
-2,715
-0.8% -$104K 0.09% 279
2025
Q1
$12.9M Buy
332,079
+2,479
+0.8% +$90.8K 0.09% 258
2024
Q4
$11.1M Sell
329,600
-1,388
-0.4% -$50K 0.07% 277
2024
Q3
$13.5M Sell
330,988
-326
-0.1% -$13.3K 0.09% 224
2024
Q2
$12.8M Hold
331,314
0.09% 230
2024
Q1
$14.2M Hold
331,314
0.1% 216
2023
Q4
$12.3M Buy
331,314
+764
+0.2% +$27.4K 0.09% 222
2023
Q3
$12M Hold
330,550
0.09% 212
2023
Q2
$11.8M Buy
330,550
+950
+0.3% +$34.1K 0.08% 219
2023
Q1
$11.7M Hold
329,600
0.09% 214
2022
Q4
$11.6M Sell
329,600
-2,360
-0.7% -$78.6K 0.09% 205
2022
Q3
$9.77M Sell
331,960
-2
-0% -$76 0.08% 227
2022
Q2
$18.1M Sell
331,962
-3
-0% -$166 0.14% 174
2022
Q1
$18.1M Sell
331,965
-2,757
-0.8% -$150K 0.12% 192
2021
Q4
$18.5M Sell
334,722
-2,248
-0.7% -$117K 0.12% 188
2021
Q3
$16.1M Sell
336,970
-35,080
-9% -$1.76M 0.11% 199
2021
Q2
$18.5M Sell
372,050
-3,120
-0.8% -$150K 0.12% 193
2021
Q1
$16.7M Sell
375,170
-912
-0.2% -$41.4K 0.11% 200
2020
Q4
$17.3M Sell
376,082
-52,297
-12% -$2.4M 0.13% 182
2020
Q3
$20.2M Sell
428,379
-471
-0.1% -$23.6K 0.17% 153
2020
Q2
$21.9M Hold
428,850
0.19% 140
2020
Q1
$20.3M Sell
428,850
-2,160
-0.5% -$115K 0.22% 129
2019
Q4
$25.3M Sell
431,010
-7,680
-2% -$427K 0.2% 135
2019
Q3
$23.4M Hold
438,690
0.19% 134
2019
Q2
$21.9M Sell
438,690
-1,164
-0.3% -$58.4K 0.21% 138
2019
Q1
$23M Sell
439,854
-115
-0% -$5.75K 0.23% 134
2018
Q4
$21M Sell
439,969
-41,390
-9% -$2.04M 0.23% 132
2018
Q3
$24.2M Sell
481,359
-42,591
-8% -$2.16M 0.22% 135
2018
Q2
$26.4M Buy
523,950
+580
+0.1% +$29.2K 0.25% 131
2018
Q1
$25.6M Buy
523,370
+80
+0% +$3.73K 0.25% 129
2017
Q4
$23.2M Sell
523,290
-9,008
-2% -$416K 0.22% 134
2017
Q3
$27M Sell
532,298
-35
-0% -$1.78K 0.27% 122
2017
Q2
$28.7M Sell
532,333
-1,190
-0.2% -$63.4K 0.31% 115
2017
Q1
$28.1M Buy
533,523
+80
+0% +$4.06K 0.3% 109
2016
Q4
$25.7M Sell
533,443
-1,440
-0.3% -$71.1K 0.29% 112
2016
Q3
$28.8M Hold
534,883
0.35% 101
2016
Q2
$29M Buy
534,883
+3,900
+0.7% +$205K 0.37% 100
2016
Q1
$26.9M Sell
530,983
-141,280
-21% -$7.04M 0.37% 98
2015
Q4
$33.9M Hold
672,263
0.47% 87
2015
Q3
$32.3M Sell
672,263
-720
-0.1% -$37.5K 0.49% 88
2015
Q2
$35M Hold
672,983
0.47% 85
2015
Q1
$38.8M Buy
672,983
+4,697
+0.7% +$269K 0.55% 69
2014
Q4
$35.7M Sell
668,286
-1,057
-0.2% -$59.1K 0.52% 66
2014
Q3
$38.5M Sell
669,343
-240,136
-26% -$14.7M 0.59% 55
2014
Q2
$60.8M Sell
909,479
-1,255
-0.1% -$84.9K 0.91% 28
2014
Q1
$60.8M Hold
910,734
0.97% 28
2013
Q4
$60.8M Sell
910,734
-1,024
-0.1% -$66.4K 1.01% 22
2013
Q3
$57.2M Sell
911,758
-76,649
-8% -$4.93M 1.1% 19
2013
Q2
$61.7M Buy
+988,407
New +$62.7M 1.3% 13

Other funds holding GSK

Silvercrest Asset Management's GSK Position: Q1 2026 in Review

Silvercrest Asset Management reduced its GSK (GSK) stake by 4.5% in Q1 2026, selling an estimated $801K and leaving 313,984 shares worth $17.3M. The position accounts for 0.13% of the portfolio, ranked #215.

Silvercrest Asset Management first reported a position in GSK in Q2 2013 and has held it in 52 quarters since. The position peaked at $61.7M in Q2 2013. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Silvercrest Asset Management held 313,984 shares of GSK worth $17.3M as of Q1 2026.
  • Silvercrest Asset Management sold 14,780 GSK shares in Q1 2026, an estimated $801K.
  • GSK made up 0.13% of Silvercrest Asset Management's portfolio in Q1 2026, its #215 holding.
  • Silvercrest Asset Management first reported a position in GSK in Q2 2013 and has held it in 52 quarters since.
  • Silvercrest Asset Management's GSK position peaked at $61.7M in Q2 2013.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Silvercrest Asset Management's 13F filing for Q1 2026, filed 15 May 2026.